ACST

Acasti Pharma, Inc.

ACST | $2.86 0.35% 0.35% 4.5K

(0.0% 1d) (-15.5% 1m) (1.0% 1y) (0.0% 2d) (1.1% 3d) (0.3% 7d) (-54.73% volume)
Earnings Calendar: 2023-06-21
Market Cap: $ 26,882,295
http://www.acastipharma.com
Sec Filling | Patents | 32 employees

(CA) Acasti Pharma, Inc. engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.

cardiovascular

add to watch list Paper trade email alert is off

Press-releases

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
Published: 2024-02-12 (Crawled : 13:00) - globenewswire.com
ACST | $2.86 0.35% 0.35% 4.5K

Health Technology

| 17.55% | O: -0.41% H: 14.75% C: 6.97%
business financial results

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial
Published: 2024-02-01 (Crawled : 13:00) - globenewswire.com
ACST | $2.86 0.35% 0.35% 4.5K

Health Technology

| 16.13% | O: -0.4% H: 0.4% C: -0.81%
gtx-104 trial

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON TrialAccepted for Presentation at the 2024 International Stroke Conference
Published: 2024-02-01 (Crawled : 21:00) - biospace.com/
ACST | $2.86 0.35% 0.35% 4.5K

Health Technology

| 16.13% | O: -0.4% H: 0.4% C: -0.81%
gtx-104 conference stroke presentation international

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
Published: 2023-12-13 (Crawled : 13:00) - globenewswire.com
ACST | $2.86 0.35% 0.35% 4.5K

Health Technology

| 33.33% | O: -1.39% H: 2.35% C: -0.47%

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
Published: 2023-11-13 (Crawled : 13:00) - globenewswire.com
ACST | $2.86 0.35% 0.35% 4.5K

Health Technology

| 29.51% | O: -3.76% H: 1.4% C: 0.47%
business financial results

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial
Published: 2023-10-23 (Crawled : 12:00) - globenewswire.com
ACST | $2.86 0.35% 0.35% 4.5K

Health Technology

| 18.52% | O: 0.0% H: 0.41% C: -1.81%
gtx-104 trial

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)
Published: 2023-10-04 (Crawled : 12:00) - globenewswire.com
ACST | $2.86 0.35% 0.35% 4.5K

Health Technology

| 8.27% | O: -0.75% H: 5.3% C: -1.89%
gtx-104 rare pharma treatment potential

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)Virtual Webinar to Take Place October 11, 2023 at 2:00pm ET
Published: 2023-10-04 (Crawled : 15:00) - biospace.com/
ACST | $2.86 0.35% 0.35% 4.5K

Health Technology

| 8.27% | O: -0.75% H: 5.3% C: -1.89%
gtx-104 rare pharma treatment potential

Acasti Announces $7.5 Million Private Placement Equity Financing
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
ACST | $2.86 0.35% 0.35% 4.5K

Health Technology

| 61.8% | O: 19.1% H: 21.7% C: 13.68%

Acasti to Participate in the H.C. Wainwright Global Investment Conference
Published: 2023-09-06 (Crawled : 12:00) - globenewswire.com
ACST | $2.86 0.35% 0.35% 4.5K

Health Technology